ClinicalTrials.gg

Program

Clarithromycin

Also written as “clarithromycin”, “Clarithromycin ER 500 mg tablets” and “Clarithromycin 500mg”.

Its studies are mostly in Mycobacterium avium-intracellulare Infection · Infections · HIV Infections · Bronchiectasis · Crohn Disease, led by 19 companies.

Furthest: phase 3, since Mar 22, 200839 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbott50 open or runningphase 3since Mar 22, 2008Nov 2, 1999none ahead
Sun Pharmaceutical Industries50 open or runningphase 1since Oct 15, 2008Oct 15, 2008none ahead
Teva Pharmaceutical Industries40 open or runningphase 1since Feb 2, 2009Feb 2, 2009none ahead
Pfizer30 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Viatris30 open or runningphase 1since Mar 31, 2008Mar 31, 2008none ahead
Boehringer Ingelheim20 open or runningphase 1since Nov 2, 1999Nov 2, 1999none ahead
Hikma Pharmaceuticals20 open or runningno phasesince Sep 20, 2007Sep 20, 2007none ahead
HK inno.N20 open or runningphase 1since Jan 7, 2014Jan 7, 2014none ahead
Johnson & Johnson20 open or runningphase 1since Jan 15, 2015Jan 15, 2015none ahead
Novartis20 open or runningphase 1since Apr 13, 2009Apr 13, 2009none ahead
antios-therapeutics-inc10 open or runningphase 1since Oct 28, 2021Oct 28, 2021none ahead
Italfarmaco10 open or runningphase 1since Apr 26, 2023Apr 26, 2023none ahead
Jiangsu HengRui Medicine11 open or runningphase 1since Jul 6, 2026Jul 6, 2026none ahead
phathom-pharmaceuticals-inc10 open or runningphase 3since Nov 15, 2019Nov 15, 2019none ahead
PTC Therapeutics10 open or runningphase 1since Nov 4, 2014Nov 4, 2014none ahead
redhill-biopharma-limited10 open or runningphase 3since Dec 26, 2016Dec 26, 2016none ahead
shandong-luoxin-pharmaceutical-group-stock-co-ltd10 open or runningphase 1since Jun 2, 2023Jun 2, 2023none ahead
Sihuan Pharmaceutical Holdings Group10 open or runningphase 1since May 15, 2020May 15, 2020none ahead
Yuhan10 open or runningphase 1since Aug 8, 2013Aug 8, 2013none ahead

Also a collaborator on its studies: genpharm-ulc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 25 studies since Nov 2, 1999.

  1. Aug 8, 2013Yuhan's first study: phase 1 study in HealthyNew to YuhanYuhan · NCT01921647 · 95 enrolled · Korea, Republic of
  2. Jan 7, 2014HK inno.N's first study: phase 1 study in HealthyNew to HK inno.NHK inno.N · NCT02052336 · 24 enrolled · Korea, Republic of
  3. Sep 25, 2014Phase 1 study in HealthyBoehringer Ingelheim · NCT02251769 · 24 enrolled
  4. Nov 4, 2014PTC Therapeutics's first study: phase 1 study in Healthy VolunteersNew to PTC TherapeuticsPTC Therapeutics · NCT02286635 · 58 enrolled · United States
  5. Jan 15, 2015Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT02343289 · 18 enrolled · Belgium
  6. Dec 13, 2016Phase 1 study in Drug InteractionHK inno.N · NCT03011996 · 60 enrolled · Korea, Republic of
  7. Dec 26, 2016redhill-biopharma-limited's first study: phase 3 study in Crohn DiseaseNew to redhill-biopharma-limitedredhill-biopharma-limited · NCT03009396 · 54 enrolled · United States, Canada, Czechia and more
  8. Jan 9, 2019Phase 1 study in HealthyJohnson & Johnson · NCT03800550 · 16 enrolled · Belgium
  9. Nov 15, 2019phathom-pharmaceuticals-inc's first study: phase 3 study in Helicobacter Pylori InfectionNew to phathom-pharmaceuticals-incphathom-pharmaceuticals-inc · NCT04167670 · 1,046 enrolled · United States, Bulgaria, Czechia and more
  10. May 15, 2020Sihuan Pharmaceutical Holdings Group's first study: phase 1 study in Healthy Male VolunteersNew to Sihuan Pharmaceutical Holdings GroupSihuan Pharmaceutical Holdings Group · NCT04444011 · 32 enrolled
  11. Oct 28, 2021antios-therapeutics-inc's first study: phase 1 study in Drug Drug InteractionNew to antios-therapeutics-incantios-therapeutics-inc · NCT05137600 · 36 enrolled · Canada
  12. Apr 26, 2023Italfarmaco's first study: phase 1 study in Drug Drug InteractionNew to ItalfarmacoItalfarmaco · NCT05845567 · 20 enrolled · Portugal
  13. Jun 2, 2023shandong-luoxin-pharmaceutical-group-stock-co-ltd's first study: phase 1 study in HealthyNew to shandong-luoxin-pharmaceutical-group-stock-co-ltdshandong-luoxin-pharmaceutical-group-stock-co-ltd · NCT05915871 · 22 enrolled · China
  14. Jul 6, 2026Jiangsu HengRui Medicine's first study: phase 1 study in Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary DiseaseNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07696091 · 40 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule

Studies

All 39 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07696091Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease · China1Not yet recruitingJiangsu HengRui MedicineSep 202640
NCT05915871Healthy · China1Completedshandong-luoxin-pharmaceutical-group-stock-co-ltdApr 28, 202322
NCT05845567Drug Drug Interaction · Portugal1CompletedItalfarmacoMay 8, 202220
NCT05137600Drug Drug Interaction · Canada1Completedantios-therapeutics-incDec 23, 202136
NCT04444011Healthy Male Volunteers1UNKNOWNSihuan Pharmaceutical Holdings GroupSep 30, 202032
NCT04167670Helicobacter Pylori Infection · United States, Bulgaria, Czechia and more3Completedphathom-pharmaceuticals-incMar 10, 20211,046
NCT03800550Healthy · Belgium1CompletedJohnson & JohnsonJun 4, 201916
NCT03009396Crohn Disease · United States, Canada, Czechia and more3Completedredhill-biopharma-limitedNov 13, 201854
NCT03011996Drug Interaction · Korea, Republic of1CompletedHK inno.NFeb 201760
NCT02343289Healthy · Belgium1CompletedJohnson & JohnsonApr 201518
NCT02286635Healthy Volunteers · United States1CompletedPTC TherapeuticsDec 201458
NCT02251769Healthy1CompletedBoehringer IngelheimSep 200324
NCT02052336Healthy · Korea, Republic of1CompletedHK inno.NJan 201424
NCT01921647Healthy · Korea, Republic of1CompletedYuhanNov 201395
NCT00881738Healthy1CompletedNovartisJun 200232
NCT00881179Healthy1CompletedNovartisJun 200224
NCT00840411Healthy · United States1CompletedTeva Pharmaceutical IndustriesOct 200266
NCT00840216Healthy · United States1CompletedTeva Pharmaceutical IndustriesAug 200222
NCT00836706Healthy · United States1CompletedTeva Pharmaceutical IndustriesJul 200224
NCT00835692Healthy · United States1CompletedTeva Pharmaceutical IndustriesSep 200260
NCT00775372Healthy · India–CompletedSun Pharmaceutical IndustriesOct 200540
NCT00775255Healthy · India–CompletedSun Pharmaceutical IndustriesSep 200540
NCT00774696Healthy · United States–CompletedSun Pharmaceutical IndustriesDec 200224
NCT00774644Healthy · United States–CompletedSun Pharmaceutical IndustriesJan 200333
NCT00774189Healthy · India1CompletedSun Pharmaceutical IndustriesAug 200332
NCT00648960Healthy · Canada1CompletedViatrisJul 200364
NCT00648830Healthy · Canada1CompletedViatrisJun 200432
NCT00648128Healthy · Canada1CompletedViatrisMar 200344
NCT00645086Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB). · United States, Canada, Puerto Rico3CompletedAbbottApr 2004465
NCT00644553Acute Bacterial Sinusitis (ABS) · United States, Canada, Greece and more3CompletedAbbottMar 2004437
NCT00643227Pneumonia · United States, Argentina, Canada and more3CompletedPfizer504
NCT00602498Infections · United States–CompletedHikma PharmaceuticalsMar 200328
NCT00601315Infections · United States–CompletedHikma PharmaceuticalsMay 200340
NCT00002336HIV Infections · United States–CompletedAbbottNov 1994
NCT00002331HIV Infections · United States, Puerto Rico–CompletedAbbottMar 1995
NCT00002194HIV Infections · United States1CompletedBoehringer Ingelheim36
NCT00002140Mycobacterium avium-intracellulare Infection · United States3CompletedPfizer
NCT00002101Mycobacterium avium-intracellulare Infection · United States3CompletedPfizer450
NCT00000971Mycobacterium avium-intracellulare Infection · United States1CompletedAbbott24

How it is read

Names in the registry

  • “Clarithromycin”, 23 entries
  • “clarithromycin”, 2 entries
  • “Clarithromycin ER 500 mg tablets”, 2 entries
  • “Clarithromycin 500mg”, 2 entries
  • “RSS0343 Tablet; Clarithromycin Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.